The draft LCD applies to advanced cancer patients who are covered by Medicare for next-generation sequencing of tumor tissue, but have insufficient or unavailable tissue samples.
Read More
The tests will use patient breath samples to identify individual biomarkers that can predict a spectrum of diseases.
Read More
Nano-Signature Discovery Could Revolutionize Cancer Diagnosis A quick and easy test to...
Read More
The findings demonstrated what causes some lung cancer patients to have an intrinsic resistance to the drug osimertinib.
Read More
Individuals identified with VeriStrat poor results had significantly lower overall survival when treated with immune checkpoint inhibitor-based regimens.
Read More